[HTML][HTML] Hydrophilic or lipophilic statins?
E Climent, D Benaiges, J Pedro-Botet - Frontiers in cardiovascular …, 2021 - frontiersin.org
Drugs can be classified as hydrophilic or lipophilic depending on their ability to dissolve in
water or in lipid-containing media. The predominantly lipophilic statins (simvastatin …
water or in lipid-containing media. The predominantly lipophilic statins (simvastatin …
Statins and inflammation
M Satny, JA Hubacek, M Vrablik - Current atherosclerosis reports, 2021 - Springer
Abstract Purpose of Review Chronic inflammation has been recognized as one of the most
important pathophysiological mechanisms' initiation and progression of atherosclerosis …
important pathophysiological mechanisms' initiation and progression of atherosclerosis …
[HTML][HTML] Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized …
Background Technological advances in arterial wall imaging permit the opportunity to
visualize coronary atherosclerotic plaque with sufficient resolution to characterize both its …
visualize coronary atherosclerotic plaque with sufficient resolution to characterize both its …
High-risk coronary plaque regression after intensive lifestyle intervention in nonobstructive coronary disease: a randomized study
Objectives The authors sought to study the impact of diet and lifestyle intervention on
changes in atherosclerotic plaque volume and composition. Background Lifestyle and diet …
changes in atherosclerotic plaque volume and composition. Background Lifestyle and diet …
Ultrasound methods in the evaluation of atherosclerosis: From pathophysiology to clinic
G Cismaru, T Serban, A Tirpe - Biomedicines, 2021 - mdpi.com
Atherosclerosis is a key pathological process that causes a plethora of pathologies,
including coronary artery disease, peripheral artery disease, and ischemic stroke. The silent …
including coronary artery disease, peripheral artery disease, and ischemic stroke. The silent …
Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography
F Gao, ZJ Wang, XT Ma, H Shen, LX Yang… - Lipids in Health and …, 2021 - Springer
Background Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been
demonstrated to produce significantly greater reduction in LDL cholesterol levels and …
demonstrated to produce significantly greater reduction in LDL cholesterol levels and …
The role of statins in the differentiation and function of bone cells
S Chamani, L Liberale, L Mobasheri… - European journal of …, 2021 - Wiley Online Library
Abstract Background Statins are 3‐Hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA)
reductase inhibitors blocking cholesterol biosynthesis in hepatic cells, thereby causing an …
reductase inhibitors blocking cholesterol biosynthesis in hepatic cells, thereby causing an …
Coronary computer tomography angiography in 2021—acquisition protocols, tips and tricks and heading beyond the possible
S Giusca, M Schuetz, F Kronbach, D Wolf, P Nunninger… - Diagnostics, 2021 - mdpi.com
Recent technological advances, together with an increasing body of evidence from
randomized trials, have placed coronary computer tomography angiography (CCTA) in the …
randomized trials, have placed coronary computer tomography angiography (CCTA) in the …
The emerging role of CT-based imaging in adipose tissue and coronary inflammation
A large body of evidence arising from recent randomized clinical trials demonstrate the
association of vascular inflammatory mediators with coronary artery disease (CAD) …
association of vascular inflammatory mediators with coronary artery disease (CAD) …
Efficacy and safety of lipid-lowering drugs of different intensity on clinical outcomes: a systematic review and network meta-analysis
W Ma, Q Pan, D Pan, T Xu, H Zhu, D Li - Frontiers in Pharmacology, 2021 - frontiersin.org
There have been many meta-analyses for statins, ezetimibe and proprotein convertase
subtilisin/kexin type 9 inhibitors (PCSK9i) to evaluate clinical outcomes, but the efficacy and …
subtilisin/kexin type 9 inhibitors (PCSK9i) to evaluate clinical outcomes, but the efficacy and …